Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (275)

« Back to Publications

Single-cycle, pseudotyped reporter influenza virus to facilitate evaluation of treatment strategies for avian influenza, Ebola and other highly infectious diseases in vivo.

Tan TK. et al, (2025), Front Immunol, 16

Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.

Moiseenko A. et al, (2025), Eur Respir J, 65

™LenticlairT-ON: An extension trial examining long-term safety and efficacy outcomes associated with an inhaled F/HN-pseudotyped lentiviral vector for CF gene therapy in people with CF

Davies JC. et al, (2025), HUMAN GENE THERAPY, 36, E352 - E353

Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial.

Davies JC. et al, (2024), Am J Respir Crit Care Med, 210, 1398 - 1408

Novel Buffer Formulations for Improved Recombinant Lentiviral Vector Stability and In Vivo Delivery to the Murine Lungs

Miah KM. et al, (2023), MOLECULAR THERAPY, 31, 760 - 760

Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection.

Du Y. et al, (2022), Thorax, 77, 1229 - 1236

Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice.

Ogger PP. et al, (2022), Eur J Immunol, 52, 1768 - 1775

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors.

Munday RJ. et al, (2022), Mol Ther Methods Clin Dev, 26, 239 - 252

Progress in Respiratory Gene Therapy.

McLachlan G. et al, (2022), Hum Gene Ther, 33, 893 - 912

Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression.

Lund-Palau H. et al, (2022), Mol Ther Methods Clin Dev, 25, 382 - 391

RNA-seq analysis of the human surfactant air-liquid interface culture reveals alveolar type II cell-like transcriptome.

Munis AM. et al, (2022), Mol Ther Methods Clin Dev, 24, 62 - 70

Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice.

Du Y. et al, (2022), Front Immunol, 13

Optimisation of lentiviral vectors for gene therapy of pulmonary fibrosis

Dickinson P. et al, (2022), HUMAN GENE THERAPY, 33, A197 - A198

Preclinical optimisation of lentiviral gene therapy delivery for surfactant deficiencies in piglets

McDougall C. et al, (2022), HUMAN GENE THERAPY, 33, A196 - A196

erosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes.

Le Gall T. et al, (2021), Pharmaceutics, 14

Load More

1
2
3
4
5
6
7
...
»